Intercept Pharmaceuticals Inc Insider ownership
What is the Insider ownership of Intercept Pharmaceuticals Inc?
The Insider ownership of Intercept Pharmaceuticals Inc is 4.50%
What is the definition of Insider ownership?
Insider Ownership is calculated as the total number of shares owned by insiders (shareholders who own more than 5% of the corporation or an officer or director of the company) divided by the total Shares Outstanding.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Insider ownership of companies in the Health Care sector on NASDAQ compared to Intercept Pharmaceuticals Inc
What does Intercept Pharmaceuticals Inc do?
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Companies with insider ownership similar to Intercept Pharmaceuticals Inc
- ATTRAQT plc has Insider ownership of 4.50%
- Colony Capital has Insider ownership of 4.50%
- Deutsche Pfandbriefbank AG has Insider ownership of 4.50%
- BGSF Inc has Insider ownership of 4.50%
- Macquarie has Insider ownership of 4.50%
- Stepan Co has Insider ownership of 4.50%
- Intercept Pharmaceuticals Inc has Insider ownership of 4.50%
- Stoneridge has Insider ownership of 4.51%
- RigNet Inc has Insider ownership of 4.51%
- Marin Software Inc has Insider ownership of 4.51%
- Plus500 has Insider ownership of 4.51%
- Detection Technology Oyj has Insider ownership of 4.51%
- Banimmo SA has Insider ownership of 4.51%